How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,549 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. (Full text)

Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disorder with progressive weakness. Acute-onset CIDP resembles Guillain-Barre syndrome (GBS), a rapidly progressive disorder, and follows a chronic course. To our knowledge, no case of acute-onset CIDP in hantavirus and hepatitis B virus (HBV) coinfection has been reported previously.We (...) report a case of acute-onset CIDP that was initially diagnosed as GBS.A 44-year-old male logger complained of acute quadriplegia and dyspnea. Mechanical ventilation was initiated. He was an HBV carrier with mild elevation of hepatic enzyme, and positive for hantavirus antibody. He was diagnosed with GBS and immunoglobulin therapy was administered.After 8 months, quadriplegia and hypesthesia recurred. Immunoglobulin therapy at this time had no effect, but steroid therapy had some effect.A diagnosis

2016 Medicine PubMed

102. Association of chronic hepatitis B virus infection with preterm birth: our experience and meta-analysis. (PubMed)

Association of chronic hepatitis B virus infection with preterm birth: our experience and meta-analysis. To assess the association of chronic hepatitis B virus (HBV) infection with preterm birth (PTB).A cohort of 20,498 pregnant women (497 HBV carriers with 20,001 non-HBV controls) with normal alanine aminotransferase (ALT) levels was selected from the Obstetrics & Gynecology Hospital of Nantong University. The clinical parameters and PTB incidence were compared between HBV carriers and non-HBV (...) subjects. For the meta-analysis, we searched the PubMed, Ovid and Cochrane Library databases for studies comparing PTB incidence between individuals with chronic HBV infection and non-HBV subjects.HBV carriers were slightly older and had slightly higher ALT levels within normal limits. The body mass index, education and history of pregnancy between HBV carrier and non-HBV groups were comparable. PTB incidence was not associated with HBV carrier status [relative risk (RR) 0.98, 95% confidence interval

2016 Journal of perinatal medicine

103. Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics…

it’s been around ten years later are the chances of me having it low as it hasn’t came up yet? I know it can lay dormant but not sure how long for Hello: Though not advisable, there is a low chance that you became infected. If you became infected at that time, your prior test for hepatitis B would have shown signs of infection. If you are concerned, please get tested again and also get vaccinated so you are forever protected against hepatitis B. Good luck. Hi, I am chronic hepa B carrier since 2014 (...) Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics… Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics - Hepatitis B Foundation , Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics Image courtesy of dream designs at FreeDigitalPhotos.net If you’ve just been diagnosed with hepatitis B after a routine blood test or following a , you may be feeling overwhelmed with information about this complicated infection

2016 hepbblog

104. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. (Full text)

Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. Interleukin-33 (IL-33) and ST2 have been demonstrated to be associated with liver damage. However, their potential value in hepatitis B virus (HBV) infection remains unknown. This study was designed to investigate the change of serum IL-33 and ST2 levels in the natural course of chronic HBV infection.A total of 120 patients with chronic hepatitis B (CHB), 20 chronic hepatitis B virus (...) of ALT, IL-33 and ST2 were compared between patients with HBeAg-positive CHB and HBeAg-negative CHB.Our study revealed that the serum levels of IL-33 and ST2 varied in different courses of chronic hepatitis B virus infection. The serum levels of IL-33 and ST2 elevated as serum ALT levels increased in patients with CHB. They might indicate liver damage for patients with CHB, just like ALT.

2016 BMC Infectious Diseases PubMed

105. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil (Full text)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including (...) . The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective.

2016 Memórias do Instituto Oswaldo Cruz PubMed

106. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection (Full text)

, chronic hepatitis B (CHB) patients, as well as asymptomatic HBV carriers (ASCs). We observed dynamic changes of T-bet, PD-1, IFN-γ and perforin in acute stage and recovery stage of acute hepatitis B (AHB).Comparing with other cohorts, HBV-specific CD8+ T cells from rAHB demonstrated a superior ability in T-bet, IFN-γ and perforin expression, but an inferior ability in PD-1 expression. In the CHB group, the level of T-bet has a linear relationship with the level of PD-1, IFN-γ and HBV DNA, respectively (...) T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection The mechanisms leading to virus-specific CD8+ T cell dysfuction in chronic hepatitis B virus (HBV) infection remain to be elucidated. Our study focused on the role of transcription factor T-bet in HBV infection because it is a crucial regulator of T cell immunity.We assessed the expression of T-bet along with PD-1, IFN-γ and perforin, in HBV-specific CD8+ T cells from resolved acute hepatitis B (rAHB) patients

2016 Virology journal PubMed

107. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus (Full text)

Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population. Carriers of the virus are at risk for life-threatening complications, and developing curative treatment remains a priority. The main shortcoming of licensed therapies is that they do not affect viral covalently closed circular DNA (cccDNA), a stable intermediate of replication. Harnessing gene editing

2016 Molecular Therapy PubMed

108. Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You?

Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? - Hepatitis B Foundation , , , Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? Image courtesy of Praisaeng, at FreeDigitalPhotos.net. If you have been diagnosed with chronic hepatitis B, your doctor has probably run several that show if the infection is harming your liver and identify what stage of infection you (...) test. Labs usually measure down to less than 200 IU/mL. Below the threshold, the viral load is considered “undetectable” – something everyone with chronic hepatitis B wants to hear. How HBV DNA results are presented mathematically on your lab report can be confusing. Because the amount of virus in the blood may be very high – in the millions or billions – the result may be displayed as an exponent or a log, rather than a whole number. You may need to convert these numbers to fully understand them

2016 hepbblog

109. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey (Full text)

Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors.This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral (...) therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant.Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males

2016 Health and quality of life outcomes PubMed

110. Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection (Full text)

Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection There are ~350 million chronic carriers of hepatitis B (HBV). While a prophylactic vaccine and drug regimens to suppress viremia are available, chronic HBV infection is rarely cured. HBV's limited host tropism leads to a scarcity of susceptible small animal models and is a hurdle to developing curative therapies. Mice that support engraftment with human hepatoctyes have

2016 Virology PubMed

111. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study (Full text)

Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study Whether the progression of advanced pancreatic ductal adenocarcinoma (PDAC) patients could be affected by HBV exposure remains to be determined. Therefore, we conducted this study to assess the effect of HBV infection on PDAC progression among a large cohort in China.A multicenter cohort study was conducted to explore whether (...) liver metastasis and overall survival in locally advanced and metastatic PDAC could be affected by HBV infection. In this study, we collected 1,526 advanced PDAC patients at three participating hospitals - Shanghai Cancer Center, Changhai Hospital and Ruijin Hospital from 2004 to 2013. The association between HBV status and advanced PDAC progression was then examined.In multivariable Logistic regression model, chronic hepatitis B(CHB) infection was inversely associated with synchronous liver

2016 Oncotarget PubMed

112. Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report (Full text)

Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report Alpha-fetoprotein is produced by a variety of tumors such as hepatocellular carcinoma, hepatoblastoma, and germ cell tumors of the ovary and testes. However, we present a case of significantly elevated serum alpha-fetoprotein without evidence of malignant disease in a patient who is a carrier of chronic hepatitis B.A 60-year-old Korean man presented with markedly increased (...) patient was diagnosed with acute exacerbation of chronic hepatitis B, and we presumed that this condition might be related to extremely elevated alpha-fetoprotein. When our patient was treated with entecavir, the serum alpha-fetoprotein level immediately decreased, in parallel with the hepatitis B virus deoxyribonucleic acid copy number.We report a rare case of extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without any malignancy, and a decrease in this tumor

2016 Journal of medical case reports PubMed

113. Network Signatures of IgG Immune Repertoires in Hepatitis B Associated Chronic Infection and Vaccination Responses (Full text)

Network Signatures of IgG Immune Repertoires in Hepatitis B Associated Chronic Infection and Vaccination Responses The repertoire of IgG antibody responses to infection and vaccination varies depending on the characteristics of the immunogen and the ability of the host to mount a protective immune response. Chronic hepatitis B virus (HBV) infections are marked by persistent infection and immune tolerance to vaccination. This disease offers a unique opportunity to discover key repertoire (...) found almost exclusively among carriers. In contrast, vaccination induced significant increases of CDR-H3 cluster diversities among siblings without hepatitis B. Several vaccination-associated clone clusters were identified. Similar findings of vaccination-associated clone networks were observed in healthy adults receiving HBV boosters. These strategies can be used to identify signatures of other infectious diseases and accelerate discoveries of antibody sequences with important biomedical

2016 Scientific reports PubMed

114. Natural regression of fibrosis in chronic hepatitis B (Full text)

occur commonly, considering the dynamic clinical features of chronic hepatitis B (CHB), where inactive carrier stage normally follows aggravation of hepatitis and progression of fibrosis at the time of HBeAg seroconversion. Thus, fibrosis levels of CHB as a hepatocellular carcinoma (HCC)-surveillance marker, particularly those of the inactive stage, could be underestimated, because some of them might have been (pre)cirrhotic in the past and recovered with the natural regression of fibrosis. We argue (...) Natural regression of fibrosis in chronic hepatitis B The fibrosis of liver cirrhosis was considered to be irreversible before the anti-viral drugs showed that it is reversible when they lead to continuous suppression of viral replication and inflammation. However, several reports previously showed that fibrosis of type B liver cirrhosis was almost completely absorbed after the natural remission of chronic inflammation. This phenomenon might not be limited to exceptional patients, but rather

2016 World Journal of Gastroenterology PubMed

115. Metabolic characterization of the natural progression of chronic hepatitis B (Full text)

Metabolic characterization of the natural progression of chronic hepatitis B Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct (...) clinical phases of a chronic HBV infection-immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases-remains unexplored.To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels.Our data illustrate the strength of metabolomics to provide insight into the metabolic

2016 Genome medicine PubMed

116. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. (Full text)

Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. In the natural history of hepatitis B virus (HBV) chronic infection, the hepatocellular carcinoma (HCC) risk is unclear. We assessed incidence and predictors of HCC by a systematic review and meta-analysis.We included longitudinal studies and randomized controlled trials assessing HCC incidence in untreated patients with HBV chronic infection. Incidence rates and their 95 (...) ), respectively; (c) chronic hepatitis: 0.12 (0.0-0.27), 0.48 (0.22-0.91) and 0.49 (0.32-0.66), respectively; (d) compensated cirrhosis (Child-Pugh A): 2.03 (1.30-2.77), 2.89 (1.23-4.55) and 3.37 (2.48-4.26) respectively. Multivariate meta-regression showed a significant increase in incidence rates for age, and for status of a symptomatic carrier, chronic hepatitis and compensated cirrhosis compared to inactive carrier, but not for geographical area after adjusting for age. An increase in the incidence rates

2016 Liver international : official journal of the International Association for the Study of the Liver PubMed

117. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management (Full text)

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr (...) incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α

2017 Psoriasis (Auckland, N.Z.) PubMed

118. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series (Full text)

Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series Reactivation of viral hepatitis B (HBV) and C (HCV) has been reported in various case reports of patients with arthritis on biological therapy. The objective of this study was to describe the clinical characteristics and outcomes of arthritis patients with HBV or HCV treated with biological therapy.This is a retrospective case series including all patients above 13 years of age (...) with arthritis patients from four centers in Saudi Arabia with concurrent chronic viral hepatitis infection (HBV or HCV) who received biological agents in the rheumatology clinics during their course of their disease from duration of the disease onset until last outpatient visit up to November 2015. Demographic information, full details about the hepatitis status of each patient, rheumatic disease diagnosis and different therapies used were reviewed.We identified 10 cases each with HBV and HCV on biological

2017 European journal of rheumatology PubMed

119. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg (Full text)

Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg In a hepatitis B virus (HBV)‑infected population, persistently low expression levels of serum HBV serum antigen (HBsAg) are present, particularly in chronic asymptomatic HBV carriers (ASCs). The present study sequenced the HBV Pre‑S gene, and aimed to elucidate its features in ASCs with low HBsAg expression compared with in the established HBV Pre‑S reference gene sequences from ASCs with high HBsAg (...) clinical features of the population with low‑level HBsAg were as follows: Most were ASCs with chronic HBV infection; 97.1% were HBsAg/anti‑HBe/anti‑HBc‑positive; 82.54% carried the B genotype; and 84.13% displayed the adw serotype. The results indicated that there were novel and meaningful mutations, including co‑mutations, at numerous loci and sites in the Pre‑S gene, as well as deletion mutations in the Pre‑S2 gene. These mutations in the Pre‑S1 and Pre‑S2 gene fragments accounted for 65.38% (68/104

2018 International journal of molecular medicine PubMed

120. The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity (Full text)

The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity Excessive hepatic gluconeogenesis is a defining feature of type 2 diabetes (T2D). Most gluconeogenic flux is routed through mitochondria. The mitochondrial pyruvate carrier (MPC) transports pyruvate from the cytosol into the mitochondrial matrix, thereby gating pyruvate-driven gluconeogenesis. Disruption of the hepatocyte MPC attenuates hyperglycemia in mice during high fat diet (HFD (...) tracing to investigate the contribution of the MPC to hyperglycemia and altered hepatic TCA cycle metabolism during HFD-induced obesity.Hepatocyte MPC disruption resulted in long-term attenuation of hyperglycemia induced by HFD. HFD increased hepatic mitochondrial pyruvate utilization and TCA cycle capacity in an MPC-dependent manner. Furthermore, MPC disruption decreased progression of fibrosis and levels of transcript markers of inflammation.By contributing to chronic hyperglycemia, fibrosis

2017 Molecular metabolism PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>